Considering the increased HIF3α promoter methylation in omental tissue and cord blood and its correlation with HIF3α gene regulation, these findings highlight the potential of HIF3α methylation as a candidate biomarker for novel therapeutic targets for GDM treatment. The gene discussed is HIF3A; the disease is gestational diabetes.